Vor Biopharma Inc (VOR)
1.755
-0.02
(-0.85%)
USD |
NASDAQ |
May 02, 16:00
1.755
0.00 (0.00%)
After-Hours: 20:00
Vor Biopharma Research and Development Expense (Quarterly): 20.90M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 20.90M |
| September 30, 2023 | 27.61M |
| June 30, 2023 | 23.90M |
| March 31, 2023 | 21.92M |
| December 31, 2022 | 17.06M |
| September 30, 2022 | 16.88M |
| June 30, 2022 | 15.33M |
| March 31, 2022 | 15.28M |
| December 31, 2021 | 12.69M |
| Date | Value |
|---|---|
| September 30, 2021 | 12.92M |
| June 30, 2021 | 12.97M |
| March 31, 2021 | 8.941M |
| December 31, 2020 | 11.33M |
| September 30, 2020 | 8.142M |
| June 30, 2020 | 5.975M |
| March 31, 2020 | 6.171M |
| December 31, 2019 | 2.964M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.964M
Minimum
Dec 2019
27.61M
Maximum
Sep 2023
14.18M
Average
12.97M
Median
Jun 2021
Research and Development Expense (Quarterly) Benchmarks
| Masimo Corp | 38.00M |
| AnaptysBio Inc | 33.52M |
| Apellis Pharmaceuticals Inc | 69.28M |
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 5.554M |